# Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

> **NCT01854775** · PHASE2,PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 129 (actual)

## Conditions studied

- Acquired Immune Deficiency Syndrome (AIDS)
- HIV Infections

## Interventions

- **DRUG:** E/C/F/TAF
- **DRUG:** E/C/F/TAF (Low Dose)

## Key facts

- **NCT ID:** NCT01854775
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-06
- **Primary completion:** 2020-05-11
- **Final completion:** 2025-06-18
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01854775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01854775, "Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01854775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*